Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Boehringer Ingelheim
Mallinckrodt
McKinsey
Harvard Business School

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Patent: 8,337,814

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 8,337,814
Title:Treatment of active infections, sinusitis, rhinitis, and related neurological disorders and related compositions
Abstract: The present invention is directed to the treatment of infections and the associated symptoms of sinusitis, rhinitis and related neurological disorders of the cranial cavity and facial tissue. More specifically, the present invention is directed to aerosols that are used to treat infections and the associated symptoms of sinusitis, rhinitis and related neurological disorders of the cranial cavity and facial tissue, compositions from which the aerosols are generated and methods of generating the aerosols. In an aerosol aspect of the present invention, an aerosol for delivery to the sinus cavity of a patient is provided. The aerosol includes at least: a) one or more compounds selected from antibiotics, antifungals, leukotriene antagonists, anti-TNF compounds, antihistamines, steroidal antiinflammatories, mucolytics, estrogen, progesterone and related hormones; and, b) water The compounds are present in the water at a concentration ranging from 0.01 mg/kg to 1000 mg/kg, and the aerosol does not contain a surfactant.
Inventor(s): Osbakken; Robert Scott (Camarillo, CA), Reitz; Russell N. (Camarillo, CA), Tarrant; John C. (Camarillo, CA)
Assignee: Topical Sinus Therapeutics, Inc. (Camarillo, CA)
Application Number:12/097,230
Patent Claims:see list of patent claims

Details for Patent 8,337,814

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial Topical Sinus Therapeutics, Inc. (Camarillo, CA) 2039-02-26 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial Topical Sinus Therapeutics, Inc. (Camarillo, CA) 2039-02-26 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial Topical Sinus Therapeutics, Inc. (Camarillo, CA) 2039-02-26 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Topical Sinus Therapeutics, Inc. (Camarillo, CA) 2039-02-26 RX Orphan search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial Topical Sinus Therapeutics, Inc. (Camarillo, CA) 2039-02-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Colorcon
Boehringer Ingelheim
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.